Clinical Trial: Safety and Efficacy of RN9101 in the Treatment of Relapsed/Refractory Multiple Myeloma

U.S., June 6 -- ClinicalTrials.gov registry received information related to the study (NCT07628595) titled 'Safety and Efficacy of RN9101 in the Treatment of Relapsed/Refractory Multiple Myeloma' on June 01.

Brief Summary: This is a single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability, preliminary efficacy, pharmacokinetics, pharmacodynamics and immunogenicity of RN9101 injection for patients with relapsed/refractory multiple myeloma.

Study Start Date: July 01

Study Type: INTERVENTIONAL

Condition: Multiple Myeloma (MM)

Intervention: DRUG: RN9101 injection

Patients will receive a single intravenous infusion of RN9101 injection

Recruitment Status: NOT_YET_RECRUITING

Sponsor: The First Affiliate...